Hemostatic effect of Related donor Platelet transfusion: a retrospective cohort study

Abstract

Abstract Transfusion of HLA-matched platelets can reduce the effect of alloimmune responses on platelet transfusion efficacy, however, finding HLA-matched platelets in the population is nearly impossible. Almost all HLA-matched platelets from relatives are half-matched, but the hemostatic efficacy of relative donor platelets is unclear. Our goal was to compare the hemostatic effect of relative donated platelets and unrelated donors platelets. In this retrospective cohort study, We analyzed 31 patients who received platelet transfusions from relatives (treatment group) and 35 patients who received platelet transfusions from unrelated donors (comparison group). Except for the relatively small proportion of patients with myelodysplastic syndrome in the treatment group, baseline clinical and laboratory characteristics were similar between the two groups. Hemostasis and prevention of bleeding in the treatment group showed significant superiority (P<0.001); The number of platelets increased 24 hours after platelet transfusion in the treatment group was significantly higher than that in the comparator group (95% CI, 25.9 to 34.9 P<0.001). After 24 hours, the corrected count increments treatment group was also higher than the comparator group (95% CI, 4.0 to 8.2 P<0.001); there was no significant difference in adverse reactions of blood transfusion between the two groups. In the treatment group, the transfusion effect was better when the three sites of HLA-A, -B, and -C were identical, and the different blood types of platelet donors and recipients did not affect the transfusion effect. Relatively donated platelets have better hemostasis and prevention effects, and no increase in adverse blood transfusion reactions. It may be a better transfusion strategy for platelet refractoriness patients in emergency situations.